Movers and Shakers -- Introduced in mid-2007, this report is the newest
in the Pharma Matters series and covers the U.S. generics industry using
data and analysis from Newport Horizon Premium, the critical product
targeting the global business development system. Analysis from the Q1 2008
-- The U.S. generics market is remarkably robust but will be hit by the
current downturn in drugs innovation, which will translate into a
decline in off-patent drugs from 2012.
-- 'Super Generic' companies such as Teva and Mylan now dominate the
generics market and will be the best placed to survive any future
-- During the first quarter of 2008, final approvals were issued on 134
'A'-rated ANDAs, up from 108 the quarter before.
-- 11 new products (four combination products and seven single active
ingredient products) were subjected to paragraph IV challenges for the
first time in Q1 2008, in comparison to the challenges made to seven
new products in the last quarter of 2007.
-- During the first quarter of 2008, the largest number of ANDA approvals
went to US-based companies. Thirty different US-based corporations
received a total of 59 final ANDA approvals.
-- In the same time period, fourteen India-based companies received a
total of 36 approvals, putting India in second place.
To learn more about companies making their mark on the U.S. generics market, click on this link to read the full report: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/movers_shakers_ jan-mar08.pdf
(Due to the length, copy and paste URL into browser window.)
Who is Making the Biggest
|SOURCE Thomson Reuters|
Copyright©2008 PR Newswire.
All rights reserved